Fig. 6.
Growth response of androgen-dependent PC-82 human prostate cancer xenografts inoculated into immune deficient intact adult male nude mice (n = 10 per group), which were either un treated or supplemented with testosterone implants. Values are the mean ± SEM of the serum TT for the group. PC-82 was originally derived from a primary cancer from a hormonally năve patient with localized disease.